Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proleukin(R) Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

X
Trial Profile

Proleukin(R) Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PROCLAIM
  • Sponsors Prometheus Laboratories
  • Most Recent Events

    • 11 Jun 2019 Status changed from recruiting to completed.
    • 05 Jun 2018 Results assessing survival (n=939) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results (n=1457) assessing association of overall survival and tumor control with development of immune-related events in patients treated with IL2, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top